These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

47 related articles for article (PubMed ID: 21062670)

  • 1. Relative indices of treatment effect may be constant across different definitions of response in schizophrenia trials.
    Furukawa TA; Akechi T; Wagenpfeil S; Leucht S
    Schizophr Res; 2011 Mar; 126(1-3):212-9. PubMed ID: 21062670
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An open, large, 6-month naturalistic study of outcome in schizophrenic outpatients, treated with olanzapine.
    Krzystanek M; Krupka-Matuszczyk I
    Hum Psychopharmacol; 2011 Jan; 26(1):81-5. PubMed ID: 23055416
    [TBL] [Abstract][Full Text] [Related]  

  • 3. How to obtain NNT from Cohen's d: comparison of two methods.
    Furukawa TA; Leucht S
    PLoS One; 2011 Apr; 6(4):e19070. PubMed ID: 21556361
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Measuring social functioning with the personal and social performance scale in patients with acute symptoms of schizophrenia: interpretation of results of a pooled analysis of three Phase III trials of paliperidone extended-release tablets.
    Patrick DL; Burns T; Morosini P; Gagnon DD; Rothman M; Adriaenssen I
    Clin Ther; 2010 Feb; 32(2):275-92. PubMed ID: 20206786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed?
    Citrome L
    Clin Schizophr Relat Psychoses; 2012 Jul; 6(2):76-85. PubMed ID: 22776634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The number needed to treat for all-cause medication discontinuation in the treatment of schizophrenia: consistency across world geographies and study designs.
    Novick D; Ascher-Svanum H; Zhu B; Brnabic A; Stauffer V; Peng X; Karagianis J; Perrin E
    Pharmacopsychiatry; 2010 May; 43(3):81-5. PubMed ID: 20446228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predicting response to atypical antipsychotics based on early response in the treatment of schizophrenia.
    Kinon BJ; Chen L; Ascher-Svanum H; Stauffer VL; Kollack-Walker S; Sniadecki JL; Kane JM
    Schizophr Res; 2008 Jul; 102(1-3):230-40. PubMed ID: 18423985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
    Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
    BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy of iloperidone in the short-term treatment of schizophrenia: a post hoc analysis of pooled patient data from four phase III, placebo- and active-controlled trials.
    Citrome L; Meng X; Hochfeld M; Stahl SM
    Hum Psychopharmacol; 2012 Jan; 27(1):24-32. PubMed ID: 22161738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
    Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
    JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Benzodiazepine augmentation of antipsychotic drugs in schizophrenia: a meta-analysis and Cochrane review of randomized controlled trials.
    Dold M; Li C; Gillies D; Leucht S
    Eur Neuropsychopharmacol; 2013 Sep; 23(9):1023-33. PubMed ID: 23602690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
    Kennedy JS; Jeste D; Kaiser CJ; Golshan S; Maguire GA; Tollefson G; Sanger T; Bymaster FP; Kinon BJ; Dossenbach M; Gilmore JA; Breier A
    Int J Geriatr Psychiatry; 2003 Nov; 18(11):1013-20. PubMed ID: 14618553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone and olanzapine versus another first generation antipsychotic in patients with schizophrenia inadequately responsive to first generation antipsychotics.
    Chen JJ; Chan HY; Chen CH; Gau SS; Hwu HG
    Pharmacopsychiatry; 2012 Mar; 45(2):64-71. PubMed ID: 22086749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term antipsychotic monotherapy for schizophrenia: disease burden and comparative outcomes for patients treated with olanzapine, quetiapine, risperidone, or haloperidol monotherapy in a pan-continental observational study.
    Dossenbach M; Pecenak J; Szulc A; Irimia V; Anders M; Logozar-Perkovic D; Peciukaitiene D; Kotler M; Smulevich AB; West TM; Lowry AJ; Treuer T
    J Clin Psychiatry; 2008 Dec; 69(12):1901-15. PubMed ID: 19012820
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Predicting antipsychotic drug response - replication and extension to six weeks in an international olanzapine study.
    Leucht S; Shamsi SA; Busch R; Kissling W; Kane JM
    Schizophr Res; 2008 Apr; 101(1-3):312-9. PubMed ID: 18308513
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of antipsychotic treatment on tardive dyskinesia: a 6-month evaluation of patients from the European Schizophrenia Outpatient Health Outcomes (SOHO) Study.
    Tenback DE; van Harten PN; Slooff CJ; Belger MA; van Os J;
    J Clin Psychiatry; 2005 Sep; 66(9):1130-3. PubMed ID: 16187770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach.
    Glick ID; Correll CU; Altamura AC; Marder SR; Csernansky JG; Weiden PJ; Leucht S; Davis JM
    J Clin Psychiatry; 2011 Dec; 72(12):1616-27. PubMed ID: 22244023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses.
    Furukawa TA; Guyatt GH; Griffith LE
    Int J Epidemiol; 2002 Feb; 31(1):72-6. PubMed ID: 11914297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of pharmacological treatments for severe agitation in real-world emergency settings: protocol of individual-participant-data network meta-analysis.
    Siafis S; Wu H; Nomura N; Schneider-Thoma J; Bighelli I; Lorenz C; Dib JE; Tharyan P; Calver LA; Isbister GK; Chan EWY; Knott JC; Yap CYL; Mantovani C; Martel ML; Barbic D; Honer WG; Hansen WP; Huf G; Alexander J; Raveendran NS; Coutinho ESF; Priller J; Adams CE; Salanti G; Leucht S
    Syst Rev; 2024 Aug; 13(1):205. PubMed ID: 39095865
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.